These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23960095)

  • 1. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
    Mazard T; Causse A; Simony J; Leconet W; Vezzio-Vie N; Torro A; Jarlier M; Evrard A; Del Rio M; Assenat E; Martineau P; Ychou M; Robert B; Gongora C
    Mol Cancer Ther; 2013 Oct; 12(10):2121-34. PubMed ID: 23960095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--response.
    Gongora C
    Mol Cancer Ther; 2014 Mar; 13(3):764. PubMed ID: 24615775
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--letter.
    Smith MA
    Mol Cancer Ther; 2014 Mar; 13(3):763. PubMed ID: 24615774
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    Samalin E; Bouché O; Thézenas S; Francois E; Adenis A; Bennouna J; Taieb J; Desseigne F; Seitz JF; Conroy T; Galais MP; Assenat E; Crapez E; Poujol S; Bibeau F; Boissière F; Laurent-Puig P; Ychou M; Mazard T
    Br J Cancer; 2014 Mar; 110(5):1148-54. PubMed ID: 24407191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
    Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.
    Paule B; Castagne V; Picard V; Saffroy R; Adam R; Guettier C; Farinotti R; Bonhomme-Faivre L
    Med Oncol; 2010 Dec; 27(4):1066-72. PubMed ID: 19862647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
    Gulhati P; Zaytseva YY; Valentino JD; Stevens PD; Kim JT; Sasazuki T; Shirasawa S; Lee EY; Weiss HL; Dong J; Gao T; Evers BM
    Carcinogenesis; 2012 Sep; 33(9):1782-90. PubMed ID: 22696593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
    Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
    Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
    PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
    BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
    Pehserl AM; Ress AL; Stanzer S; Resel M; Karbiener M; Stadelmeyer E; Stiegelbauer V; Gerger A; Mayr C; Scheideler M; Hutterer GC; Bauernhofer T; Kiesslich T; Pichler M
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
    Bradshaw-Pierce EL; Pitts TM; Kulikowski G; Selby H; Merz AL; Gustafson DL; Serkova NJ; Eckhardt SG; Weekes CD
    PLoS One; 2013; 8(3):e58089. PubMed ID: 23520486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
    Chang CH; Wang Y; Zalath M; Liu D; Cardillo TM; Goldenberg DM
    Mol Cancer Ther; 2016 Aug; 15(8):1910-9. PubMed ID: 27207776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
    Gallant JN; Allen JE; Smith CD; Dicker DT; Wang W; Dolloff NG; Navaraj A; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(3):239-51. PubMed ID: 21725213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
    Canu B; Fioravanti A; Orlandi P; Di Desidero T; Alì G; Fontanini G; Di Paolo A; Del Tacca M; Danesi R; Bocci G
    Neoplasia; 2011 Mar; 13(3):217-29. PubMed ID: 21390185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
    Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
    Maitra R; Seetharam R; Tesfa L; Augustine TA; Klampfer L; Coffey MC; Mariadason JM; Goel S
    Oncotarget; 2014 May; 5(9):2807-19. PubMed ID: 24798549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.